# Janux Therapeutics, Inc. (JANX) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Janux Therapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/JANX/mda/fy2025/): filed 2026-02-26; accession 0001193125-26-076918 (https://www.sec.gov/Archives/edgar/data/1817713/000119312526076918/janx-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/JANX/mda/fy2024/): filed 2025-02-27; accession 0000950170-25-029177 (https://www.sec.gov/Archives/edgar/data/1817713/000095017025029177/janx-20241231.htm)
- [FY 2023 MD&A](/company/JANX/mda/fy2023/): filed 2024-03-08; accession 0000950170-24-028659 (https://www.sec.gov/Archives/edgar/data/1817713/000095017024028659/janx-20231231.htm)
- [FY 2022 MD&A](/company/JANX/mda/fy2022/): filed 2023-03-10; accession 0000950170-23-007311 (https://www.sec.gov/Archives/edgar/data/1817713/000095017023007311/janx-20221231.htm)
- [FY 2021 MD&A](/company/JANX/mda/fy2021/): filed 2022-03-18; accession 0000950170-22-004171 (https://www.sec.gov/Archives/edgar/data/1817713/000095017022004171/janx-20211231.htm)

Back to /company/JANX/